MDAI Earnings Prediction
The chart below shows how MDAI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MDAI sees a +2.78% change in stock price 10 days leading up to the earnings, and a -4.50% change 10 days following the report. On the earnings day itself, the stock moves by +2.10%. This data can give you a slight idea of what to expect for the next quarter's release.
MDAI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
8.17M
137.59%
9.29%
Gross Margin
44.87%
4.86%
1.24%
Operating Margin
-10.84%
-91.05%
-66.81%
Net Margin
-18.40%
-94.04%
-51.96%
EPS
-0.08
-87.69%
-50.00%
No Data Available
MDAI Earnings Analysis
Spectral AI, Inc. Class A Common Stock Corporation (MDAI.O) Earnings Conference Call
Positive
Research Revenue Surge: 1. Significant Revenue Growth: Research and development revenue for Q3 2024 rose by 138% to $8.2 million, up from $3.4 million in the same quarter last year, driven by increased activity under the BARDA Project BioShield contract.
Gross Margin Improvement: 2. Improved Gross Margin: Gross margin improved to 44.9% in Q3 2024, compared to 42.8% in the prior year, reflecting higher reimbursement rates under the BARDA PBS contract.
Operational Efficiency Improvement: 3. Reduced Operating Expenses: General and administrative expenses decreased to $4.6 million, or 55% of revenue, down from $5.6 million, or 164% of revenue, in Q3 2023, indicating improved operational efficiency.
Improved Net Loss: 4. Narrowed Net Loss: The net loss for Q3 2024 narrowed to $1.5 million, or $0.08 per share, from a net loss of $10.6 million, or $0.77 per share, in the same quarter last year, showcasing better financial management.
Share Price Surge: 5. Positive Share Price Movement: The company's share price increased by 30% from approximately $0.93 to about $1.5 per share since the new Chairman took office, reflecting growing investor confidence.
Negative
Cash Reserves Decline: 1. Declining Cash Reserves: Cash and cash equivalents decreased to $3.7 million from $4.8 million at year-end 2023, indicating a weakening cash position.
Net Loss Improvement: 2. Net Loss: The company reported a net loss of $1.5 million for Q3 2024, although improved from a net loss of $10.6 million in Q3 2023, it still reflects ongoing financial challenges.
Administrative Expense Reduction: 3. High General and Administrative Expenses: General and administrative expenses were 55% of revenue at $4.6 million, down from 164% of revenue in the previous year, but still represent a significant cost burden.
Debt Financing Impact: 4. Notes Payable: The company has approximately $6 million in notes payable, indicating a reliance on debt financing that could impact future financial stability.
FDA Submission Delay: 5. Delayed FDA Submission: The FDA submission for the DeepView system is anticipated in the first half of 2025, indicating a prolonged timeline for potential commercialization and revenue generation.
MDAI FAQs
How does MDAI typically perform around its earnings report dates?
Is Spectral AI, Inc. (MDAI) Q3 2024 Earnings Conference Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MDAI Earning Call Sentiment
Spectral AI, Inc. (MDAI) Q3 2024 Earnings Conference Call Transcript
1.0x
00:00
00:00
MDAI.O
12.32%Positive
The company has shown strong financial performance with a significant increase in research and development revenue and improved operational efficiency, reducing net loss substantially. Despite financial sustainability concerns, the optimistic revenue guidance and 30% share price increase reflect positive market sentiment. The Q&A section highlights progress towards FDA submission and expansion efforts, though some uncertainties remain. Overall, the positive financial metrics and optimistic guidance outweigh the challenges, suggesting a positive stock price movement.
